No Data
No Data
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its
Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...
Lumos Pharma | 10-Q: Quarterly report
Earnings Call Summary | Lumos Pharma(LUMO.US) Q1 2024 Earnings Conference
The following is a summary of the Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript:Financial Performance:Lumos Pharma's cash and short-term investments were at $23.2 million at the end of Q1
Lumos Pharma Plans Phase 3 Study of Growth Hormone Drug
Lumos Pharma (LUMO) said Tuesday it completed end-of-phase 2 meeting with the US Food and Drug Administration with plans to move forward with a proposal of Phase 3 study of LUM-201, an oral growth hor
Express News | Lumos Pharma Q1 2024 GAAP EPS $(1.29) Misses $(1.18) Estimate, Sales $165.00K Miss $302.60K Estimate
No Data